Nephrology Times Commentary
From the Chair
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
The benefit-risk ratio and considerations about unmet need are worth considering.
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
The first part of the dialysis moonshot is to prevent the need for dialysis.
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
Advertisement
From the Field
It is essential for nephrology practices and dialysis centers to have backup methods for processing claims.
Medicare Advantage plans are posing significant operational and financial hurdles for dialysis programs.
The choice of a billing solution, often made under the guise of cost savings, requires a thoughtful approach.
The new base rate for CY 2024 is set at $271.02, which is a 2% increase from CY 2023.
When collections waver, a facility’s financial health teeters.
Advocacy for improved reimbursement is crucial to ensuring continued access to care.
Advertisement
